RT Journal Article SR Electronic T1 Neurologic manifestations in hospitalized patients with COVID-19 JF Neurology JO Neurology FD Lippincott Williams & Wilkins SP e1060 OP e1070 DO 10.1212/WNL.0000000000009937 VO 95 IS 8 A1 Romero-Sánchez, Carlos Manuel A1 Díaz-Maroto, Inmaculada A1 Fernández-Díaz, Eva A1 Sánchez-Larsen, Álvaro A1 Layos-Romero, Almudena A1 García-García, Jorge A1 González, Esther A1 Redondo-Peñas, Inmaculada A1 Perona-Moratalla, Ana Belén A1 Del Valle-Pérez, José Antonio A1 Gracia-Gil, Julia A1 Rojas-Bartolomé, Laura A1 Feria-Vilar, Inmaculada A1 Monteagudo, María A1 Palao, María A1 Palazón-García, Elena A1 Alcahut-Rodríguez, Cristian A1 Sopelana-Garay, David A1 Moreno, Yóscar A1 Ahmad, Javaad A1 Segura, Tomás YR 2020 UL http://n.neurology.org/content/95/8/e1060.abstract AB Objective The coronavirus disease 2019 (COVID-19) has spread worldwide since December 2019. Neurologic symptoms have been reported as part of the clinical spectrum of the disease. We aimed to determine whether neurologic manifestations are common in hospitalized patients with COVID-19 and to describe their main characteristics.Methods We systematically reviewed all patients diagnosed with COVID-19 admitted to the hospital in a Spanish population during March 2020. Demographic characteristics, systemic and neurologic clinical manifestations, and complementary tests were analyzed.Results Of 841 patients hospitalized with COVID-19 (mean age 66.4 years, 56.2% men), 57.4% developed some form of neurologic symptom. Nonspecific symptoms such as myalgias (17.2%), headache (14.1%), and dizziness (6.1%) were present mostly in the early stages of infection. Anosmia (4.9%) and dysgeusia (6.2%) tended to occur early (60% as the first clinical manifestation) and were more frequent in less severe cases. Disorders of consciousness occurred commonly (19.6%), mostly in older patients and in severe and advanced COVID-19 stages. Myopathy (3.1%), dysautonomia (2.5%), cerebrovascular diseases (1.7%), seizures (0.7%), movement disorders (0.7%), encephalitis (n = 1), Guillain-Barré syndrome (n = 1), and optic neuritis (n = 1) were also reported, but less frequent. Neurologic complications were the main cause of death in 4.1% of all deceased study participants.Conclusions Neurologic manifestations are common in hospitalized patients with COVID-19. In our series, more than half of patients presented some form of neurologic symptom. Clinicians need to maintain close neurologic surveillance for prompt recognition of these complications. The mechanisms and consequences of severe acute respiratory syndrome coronavirus type 2 neurologic involvement require further studies.ACE2=angiotensin-converting enzyme receptor 2; ACEI=angiotensin-converting enzyme inhibitors; AIDP=acute inflammatory demyelinating polyneuropathy; ARB=angiotensin II receptor blockers; BBB=blood–brain barrier; CI=confidence interval; CK=creatine kinase; CKD=chronic kidney disease; COVID-19=coronavirus disease 2019; CRP=C-reactive protein; ICH=intracranial hemorrhage; ICU=intensive care unit; IgG=immunoglobulin G; IgM=immunoglobulin M; LMWH=low-molecular-weight heparin; OR=odds ratio; PNS=peripheral nervous system; rt-PCR=real-time reverse transcription–polymerase chain reaction; SARS-CoV-2=severe acute respiratory syndrome coronavirus type 2